PT010

Report
20 Pages
July 2018
Region: Global
Citeline
ID: 4775194

Drug Overview
PT010 is a fixed triple-combination product consisting of a long-acting muscarinic antagonist (LAMA [glycopyrrolate]), a long-acting beta 2 agonist (LABA [formoterol]), and an inhaled corticosteroid (ICS [budesonide]). PT010 is in Phase III development for the treatment of moderate to very severe COPD, and in Phase II development for the treatment of moderate to severe persistent asthma.

OVERVIEW

Drug Overview
Product Profiles
PT010: Chronic obstructive pulmonary disease (COPD)

LIST OF FIGURES

Figure 1: PT010 for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of PT010 for COPD
Figure 3: The authors drug assessment summary of PT010 for COPD
Figure 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: PT010 drug profile
Table 2: PT010 Phase III data in COPD
Table 3: PT010 Phase III trials in COPD
Table 4: PT010 sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9652EUR$10,000USD£8,279GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47295EUR$49,000USD£40,569GBP

Table of Contents

Related Topics

Related Reports

Anti-Asthmatics and COPD Drugs Global Market Report 2024

COPD: Update Bulletin

Pulmonary Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024

Lower Respiratory Tract Therapeutics Global Market Report 2024